𝐊𝐞𝐞𝐩𝐢𝐧𝐠 𝐩𝐚𝐜𝐞 𝐰𝐢𝐭𝐡 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧; 𝐚𝐧 𝐞𝐭𝐡𝐢𝐜𝐚𝐥 𝐝𝐢𝐥𝐞𝐦𝐦𝐚
Last month’s 13th Annual Global Pharma Regulatory Summit in Mumbai supported by TOPRA - The Organisation for Professionals in Regulatory Affairs, explored how regulation can keep pace with innovation while ensuring patient safety, accessibility and affordability.
I spoke on ATMPs and was joined by Valentin Plouchard, Shaila Choi, Meritxell Sabidó-Espin and Mark Birse who covered inspections, real world evidence, clinical trials, medical devices and AI.
My additional reflections:
𝑬𝑼 𝑷𝒉𝒂𝒓𝒎𝒂 𝒍𝒆𝒈𝒊𝒔𝒍𝒂𝒕𝒊𝒐𝒏 - 𝑹𝒆𝒈𝒖𝒍𝒂𝒕𝒐𝒓𝒚 𝒅𝒂𝒕𝒂 𝒑𝒓𝒐𝒕𝒆𝒄𝒕𝒊𝒐𝒏 (𝑹𝑫𝑷)
More favourable for drug developers now that:
✅ RDP baseline has been adjusted from the previous proposal of 6+4y to 7.5+3 years (currently 8+2y).
✅ The previous carrot/stick proposal of gaining an extra 2y RDP if launched in all EU markets has been reduced to 6m, noting it may take up to 17m to secure pricing and reimbursement (EFPIA, 2023).
𝑨𝑰: 𝑸𝒖𝒂𝒍𝒊𝒕𝒚 𝒗𝒔 𝒔𝒑𝒆𝒆𝒅
Given the risk-based approach that FDA/EMA/MHRA have adopted, it emphasizes the importance of Quality to ensure good data quality and data integrity.
Quality is already a major reputational issue for India, given the suspension of more than 350 generic drugs tested by Synapse Labs, an Indian CRO, due to deficient/insufficient data to show bioequivalence following a GCP inspection (EMA 2023 Annual Report). Anecdotally the EMA is concerned about 15 other Indian CROs.
𝑼𝑲 𝒍𝒂𝒈𝒈𝒊𝒏𝒈?
Lack of resources at MHRA have resulted in fewer overseas inspections given the high staff turnover and Brexit. This is matched by anecdotal reports of scientific advice taking 3-12 months! In contrast, FDA conduct the majority of their inspections overseas supported by their local presence in China and India.
𝑪𝑮𝑻 – 𝒉𝒐𝒍𝒚 𝒈𝒓𝒂𝒊𝒍 𝒇𝒐𝒓 𝑰𝒏𝒅𝒊𝒂?
I was impressed how Yogananth Rajendran M.Pharm.RAC at Immuneel Therapeutics Pvt. Ltd. had licensed the first-ever commercial CAR-T in India within an immature ATMP regulatory system at that time. However seeing the world's most expensive home - the Ambani family’s Mumbai tower, Antilia ($1 billion), in contrast to widespread poverty where basic healthcare and sanitation are lacking for many, it's made me wonder:
❓ 𝑰𝒔 𝒊𝒕 𝒓𝒊𝒈𝒉𝒕 𝒇𝒐𝒓 𝒍𝒐𝒘𝒆𝒓-𝒎𝒊𝒅𝒅𝒍𝒆 𝒊𝒏𝒄𝒐𝒎𝒆 𝒄𝒐𝒖𝒏𝒕𝒓𝒊𝒆𝒔 𝒍𝒊𝒌𝒆 𝑰𝒏𝒅𝒊𝒂 𝒕𝒐 𝒇𝒐𝒄𝒖𝒔 𝒐𝒏 𝑨𝑻𝑴𝑷𝒔?
❓ 𝑾𝒉𝒂𝒕’𝒔 𝒕𝒉𝒆 𝒎𝒐𝒓𝒂𝒍 𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒊𝒃𝒊𝒍𝒊𝒕𝒚, 𝒊𝒇 𝒂𝒏𝒚, 𝒐𝒏 𝑨𝑻𝑴𝑷 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒆𝒓𝒔 𝒊𝒏 𝒓𝒊𝒄𝒉𝒆𝒓 𝒄𝒐𝒖𝒏𝒕𝒓𝒊𝒆𝒔 𝒇𝒐𝒓 𝒎𝒂𝒌𝒊𝒏𝒈 𝒕𝒉𝒆𝒎 𝒂𝒄𝒄𝒆𝒔𝒔𝒊𝒃𝒍𝒆 𝒇𝒐𝒓 𝒅𝒊𝒔𝒆𝒂𝒔𝒆𝒔 𝒘𝒉𝒆𝒓𝒆 𝒕𝒉𝒆 𝒎𝒂𝒋𝒐𝒓𝒊𝒕𝒚 𝒐𝒇 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔 𝒂𝒓𝒆 𝒊𝒏 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒊𝒏𝒈 𝒄𝒐𝒖𝒏𝒕𝒓𝒊𝒆𝒔 𝒂𝒏𝒅 𝒄𝒂𝒏’𝒕 𝒂𝒇𝒇𝒐𝒓𝒅 𝒊𝒕?
Until the cost is significantly reduced, ATMPs may only be the preserve of the rich.
#innovation #biotech #advancedtherapies #ai #india
You’re a true inspiration to the community Ming! All the best